PW Medtech Group Limited — Capital/Financing Update 2020

May 10, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 華 和 順 集 團 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

COMPLETION OF MAJOR TRANSACTION DISPOSAL OF CBPO SHARES

Reference is made to the announcements dated September 19, 2019, November 7, 2019, January 23, 2020 and May 5, 2020 and the circular (the ‘‘Circular’’) dated October 18, 2019 of PW Medtech Group Limited (the ‘‘Company’’) in relation to the Disposal. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context herein requires otherwise.

The Board is pleased to announce that all conditions precedents of the Disposal have been fulfilled and the completion took place on May 8, 2020 (U.S. Eastern Time) in accordance with the terms and conditions of the Share Purchase Agreement. On the same date, the Company utilized a portion of the proceeds from the Disposal to fully prepay all outstanding principal amount and accrued interest under the loan agreement with Morgan Stanley Bank, N.A. (the ‘‘Lender’’) dated September 20, 2018 (the ‘‘Loan Agreement’’), upon which all CBPO Shares charged by the Company in favor of the Lender under the Loan Agreement were released pursuant to the terms of the Loan Agreement. Following the completion of the Disposal, the shareholding percentage of the Company in CBPO has decreased to 13.83%.

By order of the Board

PW Medtech Group Limited Yue’e Zhang Chairman & Chief Executive Officer

Hong Kong, May 10, 2020

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue’e Zhang; two nonexecutive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Zhang Xingdong and Mr. Chen Geng.